Loading…
The Nordic SentiMag trial: a comparison of super paramagnetic iron oxide
The aim of the study is to compare the efficacy of SPIO as a tracer in sentinel node biopsy (SNB) in breast cancer with Tc and patent blue in a multicentre prospective study and perform a meta-analysis of all published studies. It also aims to follow skin discoloration after SPIO injection and descr...
Saved in:
Published in: | Breast cancer research and treatment 2016-06, Vol.157 (2), p.281 |
---|---|
Main Authors: | , , , , , , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | |
---|---|
cites | |
container_end_page | |
container_issue | 2 |
container_start_page | 281 |
container_title | Breast cancer research and treatment |
container_volume | 157 |
creator | Karakatsanis, Andreas Christiansen, Peer Michael Sund, Malin Rasmussen, Nils Ryegaard Wärnberg, Fredrik Bergkvist, Leif Jørnsgård, Hjørdis Tegnelius, Daniel Fischer, Lone Pistioli, Lida Markopoulos, Christos J Hedin, Christina Daskalakis, Kosmas Eriksson, Staffan |
description | The aim of the study is to compare the efficacy of SPIO as a tracer in sentinel node biopsy (SNB) in breast cancer with Tc and patent blue in a multicentre prospective study and perform a meta-analysis of all published studies. It also aims to follow skin discoloration after SPIO injection and describe when and how it resolves. Totally 206 patients with early breast cancer were recruited. Tc and patent blue were administered in standard fashion. Patients were injected with SPIO (Sienna+) preoperatively. SNB was performed and detection rates were recorded for both methods. Skin discoloration was followed and documented postoperatively. Data extraction and subsequent meta-analysis of all previous studies were also performed. SN detection rates were similar between standard technique succeeded and SPIO both per patient (97.1 vs. 97.6 %, p = 0.76) as well as per node (91.3 vs. 93.3 %, p = 0.34), something which was not affected by the presence of malignancy. Concordance rates were also consistently high (98.0 % per patient and 95.9 % per node). Discoloring was present in 35.5 % of patients postoperatively, almost exclusively in breast conservation. It fades slowly and is still detectable in 8.6 % of patients after 15 months. Meta-analysis depicted similar detection rates (p = 0.71) and concordance rates (p = 0.82) per patient. However, it seems that SPIO is characterized by higher nodal retrieval (p < 0.001). SPIO is an effective method for the detection of SN in patients with breast cancer. It is comparable to the standard technique and seems to simplify logistics. Potential skin discoloration is something of consideration in patients planned for breast conservation. |
format | article |
fullrecord | <record><control><sourceid>gale</sourceid><recordid>TN_cdi_gale_healthsolutions_A452725414</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A452725414</galeid><sourcerecordid>A452725414</sourcerecordid><originalsourceid>FETCH-gale_healthsolutions_A4527254143</originalsourceid><addsrcrecordid>eNqNi70OgjAURjtoIv68w53cSAryI27GaFh0kZ3cwIXWlJa0JfHxxcQHcPqSc863YAGPsjzMjjxbsbVzL855kfMiYGUlCB7GtrKBJ2kv79iDtxLVCRAaM4xopTMaTAduGsnCDHDAXpOfL9J-1Vu2tGXLDpWj3W83bH-7Vpcy7FFRLQiVF86oyUujXX1O0jiP0yRKDn-HHw2gPVM</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>The Nordic SentiMag trial: a comparison of super paramagnetic iron oxide</title><source>Springer Link</source><creator>Karakatsanis, Andreas ; Christiansen, Peer Michael ; Sund, Malin ; Rasmussen, Nils Ryegaard ; Wärnberg, Fredrik ; Bergkvist, Leif ; Jørnsgård, Hjørdis ; Tegnelius, Daniel ; Fischer, Lone ; Pistioli, Lida ; Markopoulos, Christos J ; Hedin, Christina ; Daskalakis, Kosmas ; Eriksson, Staffan</creator><creatorcontrib>Karakatsanis, Andreas ; Christiansen, Peer Michael ; Sund, Malin ; Rasmussen, Nils Ryegaard ; Wärnberg, Fredrik ; Bergkvist, Leif ; Jørnsgård, Hjørdis ; Tegnelius, Daniel ; Fischer, Lone ; Pistioli, Lida ; Markopoulos, Christos J ; Hedin, Christina ; Daskalakis, Kosmas ; Eriksson, Staffan</creatorcontrib><description>The aim of the study is to compare the efficacy of SPIO as a tracer in sentinel node biopsy (SNB) in breast cancer with Tc and patent blue in a multicentre prospective study and perform a meta-analysis of all published studies. It also aims to follow skin discoloration after SPIO injection and describe when and how it resolves. Totally 206 patients with early breast cancer were recruited. Tc and patent blue were administered in standard fashion. Patients were injected with SPIO (Sienna+) preoperatively. SNB was performed and detection rates were recorded for both methods. Skin discoloration was followed and documented postoperatively. Data extraction and subsequent meta-analysis of all previous studies were also performed. SN detection rates were similar between standard technique succeeded and SPIO both per patient (97.1 vs. 97.6 %, p = 0.76) as well as per node (91.3 vs. 93.3 %, p = 0.34), something which was not affected by the presence of malignancy. Concordance rates were also consistently high (98.0 % per patient and 95.9 % per node). Discoloring was present in 35.5 % of patients postoperatively, almost exclusively in breast conservation. It fades slowly and is still detectable in 8.6 % of patients after 15 months. Meta-analysis depicted similar detection rates (p = 0.71) and concordance rates (p = 0.82) per patient. However, it seems that SPIO is characterized by higher nodal retrieval (p < 0.001). SPIO is an effective method for the detection of SN in patients with breast cancer. It is comparable to the standard technique and seems to simplify logistics. Potential skin discoloration is something of consideration in patients planned for breast conservation.</description><identifier>ISSN: 0167-6806</identifier><language>eng</language><publisher>Springer</publisher><subject>Breast cancer ; Cancer patients ; Cancer research ; Comparative analysis ; Ferric oxide ; Intellectual property ; Iron compounds ; Tracers (Biology)</subject><ispartof>Breast cancer research and treatment, 2016-06, Vol.157 (2), p.281</ispartof><rights>COPYRIGHT 2016 Springer</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784</link.rule.ids></links><search><creatorcontrib>Karakatsanis, Andreas</creatorcontrib><creatorcontrib>Christiansen, Peer Michael</creatorcontrib><creatorcontrib>Sund, Malin</creatorcontrib><creatorcontrib>Rasmussen, Nils Ryegaard</creatorcontrib><creatorcontrib>Wärnberg, Fredrik</creatorcontrib><creatorcontrib>Bergkvist, Leif</creatorcontrib><creatorcontrib>Jørnsgård, Hjørdis</creatorcontrib><creatorcontrib>Tegnelius, Daniel</creatorcontrib><creatorcontrib>Fischer, Lone</creatorcontrib><creatorcontrib>Pistioli, Lida</creatorcontrib><creatorcontrib>Markopoulos, Christos J</creatorcontrib><creatorcontrib>Hedin, Christina</creatorcontrib><creatorcontrib>Daskalakis, Kosmas</creatorcontrib><creatorcontrib>Eriksson, Staffan</creatorcontrib><title>The Nordic SentiMag trial: a comparison of super paramagnetic iron oxide</title><title>Breast cancer research and treatment</title><description>The aim of the study is to compare the efficacy of SPIO as a tracer in sentinel node biopsy (SNB) in breast cancer with Tc and patent blue in a multicentre prospective study and perform a meta-analysis of all published studies. It also aims to follow skin discoloration after SPIO injection and describe when and how it resolves. Totally 206 patients with early breast cancer were recruited. Tc and patent blue were administered in standard fashion. Patients were injected with SPIO (Sienna+) preoperatively. SNB was performed and detection rates were recorded for both methods. Skin discoloration was followed and documented postoperatively. Data extraction and subsequent meta-analysis of all previous studies were also performed. SN detection rates were similar between standard technique succeeded and SPIO both per patient (97.1 vs. 97.6 %, p = 0.76) as well as per node (91.3 vs. 93.3 %, p = 0.34), something which was not affected by the presence of malignancy. Concordance rates were also consistently high (98.0 % per patient and 95.9 % per node). Discoloring was present in 35.5 % of patients postoperatively, almost exclusively in breast conservation. It fades slowly and is still detectable in 8.6 % of patients after 15 months. Meta-analysis depicted similar detection rates (p = 0.71) and concordance rates (p = 0.82) per patient. However, it seems that SPIO is characterized by higher nodal retrieval (p < 0.001). SPIO is an effective method for the detection of SN in patients with breast cancer. It is comparable to the standard technique and seems to simplify logistics. Potential skin discoloration is something of consideration in patients planned for breast conservation.</description><subject>Breast cancer</subject><subject>Cancer patients</subject><subject>Cancer research</subject><subject>Comparative analysis</subject><subject>Ferric oxide</subject><subject>Intellectual property</subject><subject>Iron compounds</subject><subject>Tracers (Biology)</subject><issn>0167-6806</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid/><recordid>eNqNi70OgjAURjtoIv68w53cSAryI27GaFh0kZ3cwIXWlJa0JfHxxcQHcPqSc863YAGPsjzMjjxbsbVzL855kfMiYGUlCB7GtrKBJ2kv79iDtxLVCRAaM4xopTMaTAduGsnCDHDAXpOfL9J-1Vu2tGXLDpWj3W83bH-7Vpcy7FFRLQiVF86oyUujXX1O0jiP0yRKDn-HHw2gPVM</recordid><startdate>20160601</startdate><enddate>20160601</enddate><creator>Karakatsanis, Andreas</creator><creator>Christiansen, Peer Michael</creator><creator>Sund, Malin</creator><creator>Rasmussen, Nils Ryegaard</creator><creator>Wärnberg, Fredrik</creator><creator>Bergkvist, Leif</creator><creator>Jørnsgård, Hjørdis</creator><creator>Tegnelius, Daniel</creator><creator>Fischer, Lone</creator><creator>Pistioli, Lida</creator><creator>Markopoulos, Christos J</creator><creator>Hedin, Christina</creator><creator>Daskalakis, Kosmas</creator><creator>Eriksson, Staffan</creator><general>Springer</general><scope/></search><sort><creationdate>20160601</creationdate><title>The Nordic SentiMag trial: a comparison of super paramagnetic iron oxide</title><author>Karakatsanis, Andreas ; Christiansen, Peer Michael ; Sund, Malin ; Rasmussen, Nils Ryegaard ; Wärnberg, Fredrik ; Bergkvist, Leif ; Jørnsgård, Hjørdis ; Tegnelius, Daniel ; Fischer, Lone ; Pistioli, Lida ; Markopoulos, Christos J ; Hedin, Christina ; Daskalakis, Kosmas ; Eriksson, Staffan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-gale_healthsolutions_A4527254143</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Breast cancer</topic><topic>Cancer patients</topic><topic>Cancer research</topic><topic>Comparative analysis</topic><topic>Ferric oxide</topic><topic>Intellectual property</topic><topic>Iron compounds</topic><topic>Tracers (Biology)</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Karakatsanis, Andreas</creatorcontrib><creatorcontrib>Christiansen, Peer Michael</creatorcontrib><creatorcontrib>Sund, Malin</creatorcontrib><creatorcontrib>Rasmussen, Nils Ryegaard</creatorcontrib><creatorcontrib>Wärnberg, Fredrik</creatorcontrib><creatorcontrib>Bergkvist, Leif</creatorcontrib><creatorcontrib>Jørnsgård, Hjørdis</creatorcontrib><creatorcontrib>Tegnelius, Daniel</creatorcontrib><creatorcontrib>Fischer, Lone</creatorcontrib><creatorcontrib>Pistioli, Lida</creatorcontrib><creatorcontrib>Markopoulos, Christos J</creatorcontrib><creatorcontrib>Hedin, Christina</creatorcontrib><creatorcontrib>Daskalakis, Kosmas</creatorcontrib><creatorcontrib>Eriksson, Staffan</creatorcontrib><jtitle>Breast cancer research and treatment</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Karakatsanis, Andreas</au><au>Christiansen, Peer Michael</au><au>Sund, Malin</au><au>Rasmussen, Nils Ryegaard</au><au>Wärnberg, Fredrik</au><au>Bergkvist, Leif</au><au>Jørnsgård, Hjørdis</au><au>Tegnelius, Daniel</au><au>Fischer, Lone</au><au>Pistioli, Lida</au><au>Markopoulos, Christos J</au><au>Hedin, Christina</au><au>Daskalakis, Kosmas</au><au>Eriksson, Staffan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The Nordic SentiMag trial: a comparison of super paramagnetic iron oxide</atitle><jtitle>Breast cancer research and treatment</jtitle><date>2016-06-01</date><risdate>2016</risdate><volume>157</volume><issue>2</issue><spage>281</spage><pages>281-</pages><issn>0167-6806</issn><abstract>The aim of the study is to compare the efficacy of SPIO as a tracer in sentinel node biopsy (SNB) in breast cancer with Tc and patent blue in a multicentre prospective study and perform a meta-analysis of all published studies. It also aims to follow skin discoloration after SPIO injection and describe when and how it resolves. Totally 206 patients with early breast cancer were recruited. Tc and patent blue were administered in standard fashion. Patients were injected with SPIO (Sienna+) preoperatively. SNB was performed and detection rates were recorded for both methods. Skin discoloration was followed and documented postoperatively. Data extraction and subsequent meta-analysis of all previous studies were also performed. SN detection rates were similar between standard technique succeeded and SPIO both per patient (97.1 vs. 97.6 %, p = 0.76) as well as per node (91.3 vs. 93.3 %, p = 0.34), something which was not affected by the presence of malignancy. Concordance rates were also consistently high (98.0 % per patient and 95.9 % per node). Discoloring was present in 35.5 % of patients postoperatively, almost exclusively in breast conservation. It fades slowly and is still detectable in 8.6 % of patients after 15 months. Meta-analysis depicted similar detection rates (p = 0.71) and concordance rates (p = 0.82) per patient. However, it seems that SPIO is characterized by higher nodal retrieval (p < 0.001). SPIO is an effective method for the detection of SN in patients with breast cancer. It is comparable to the standard technique and seems to simplify logistics. Potential skin discoloration is something of consideration in patients planned for breast conservation.</abstract><pub>Springer</pub></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0167-6806 |
ispartof | Breast cancer research and treatment, 2016-06, Vol.157 (2), p.281 |
issn | 0167-6806 |
language | eng |
recordid | cdi_gale_healthsolutions_A452725414 |
source | Springer Link |
subjects | Breast cancer Cancer patients Cancer research Comparative analysis Ferric oxide Intellectual property Iron compounds Tracers (Biology) |
title | The Nordic SentiMag trial: a comparison of super paramagnetic iron oxide |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T08%3A09%3A00IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20Nordic%20SentiMag%20trial:%20a%20comparison%20of%20super%20paramagnetic%20iron%20oxide&rft.jtitle=Breast%20cancer%20research%20and%20treatment&rft.au=Karakatsanis,%20Andreas&rft.date=2016-06-01&rft.volume=157&rft.issue=2&rft.spage=281&rft.pages=281-&rft.issn=0167-6806&rft_id=info:doi/&rft_dat=%3Cgale%3EA452725414%3C/gale%3E%3Cgrp_id%3Ecdi_FETCH-gale_healthsolutions_A4527254143%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/&rft_galeid=A452725414&rfr_iscdi=true |